[ Inside the business ]

IQV stock analysis

IQV · Iqvia Holdings Inc.

Services-commercial physical and biological research. Growing 8%.

Watch: growth that has stopped speeding up.

The future, in 7 questions

Priced in: 0.9× sales in 5 yrs. Evidence: backlog covers it · sales +8% · 13¢ profit/$1.

01 What's priced in?0.9× sales in 5 yrs
Sales now$17.3B
Needed in 5 yrs$16.3B
Backlog$34.2B
02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Sales +8%, steady
No customer over 10%
Backlog $34.2B · 2.0× salesPrepaid $2.3BSales +8%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 13¢ per $1
'21'22'23'24'2513¢
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares −3.5%/yrDebt $16.1B
07 What could break it?3 to watch
  • Growth peaked
  • Insiders sold $31M outside pre-set plans
  • Moves strongly with the S&P 500

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth peaked.

Sales growth +8%, +9%, then +8% vs. a year ago.

What could go wrong

Few warning signs.

It has moved 1.3× the market. In the 2022 rate shock it fell 36% while the market fell 24%. Debt is heavy.

Speculative check

Not classified.

Not Self-funding because of: debt over 4× operating profit.

What they sell

60% Research And Development Solutions.

Research And Development Solutions 60% · Commercial Solutions 40% (latest quarter)

Where each dollar goes

Not available.

Cost lines aren't reported in a comparable form.

Its market

1.6× the economy.

The government expects its industry, scientific research and development services, to grow 3.1% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Maturity.

It earns cash, still invests, and pays back more than it borrows.

Earnings quality

Clean.

Its numbers don't resemble those of past manipulators. Cash covers 196¢ of each $1 of profit.

Competitive advantage

3 of 10 years.

Returns beat its 8.2% cost of capital in 3 of the last 10 years.

Future bets

4% on equipment.

$657M a year on equipment and buildings.

All figures from Iqvia Holdings Inc.'s SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.